The information about medications is for informational purposes only. We are not responsible for any potential negative consequences of their use.
- Treatment of thrush
- Treatment of Cystitis
- Treatment of menopause
- Hypothyroidism Treatment
- Treatment of Dementia
- Gammalon
- Treatment of Cervical Human Papillomavirus (HPV)
- Liver treatment
- OBESITY TREATMENT
- Treatment of Anemia
- Gout Treatment
- TREATMENT OF POLYCYSTIC OVARY SYNDROME (PCOS)
- Treatment of Endometriosis and Adenomyosis
- Treatment of Pyelonephritis
- Milanese Cocktail
- Treatment of the lungs. COPD. Emphysema.
- Intestinal Treatment
- Treatment of Bronchial Asthma
- Treatment of back pain
- Joint treatment
- Treatment of Myasthenia
- TREATMENT OF ATYPICAL PROCESSES (PDT)
- TREATMENT OF OLD AGE
- Treatment of alcohol addiction
- Treatment of Constipation
- Post-stroke condition treatment
- Alcohol withdrawal treatment
- Migraine Treatment
- Kidney Treatment
- TREATMENT OF TYPE 2 DIABETES
- TREATMENT OF INSULIN RESISTANCE
- Treatment of uterine bleeding
- Treatment of impotence
- TREATMENT OF VIRUSES AND COLDS
- Treatment of Thin Endometrium
- TREATMENT OF ACNE, PIMPLES, PROBLEMATIC SKIN OF THE FACE...
- TREATMENT OF GALLSTONE DISEASE
- Поставити запитання
Поставити запитання
Купить товар
ESAFOSFINA EZAFOSFINA 5g/50ml (ITALY)
46у.е. (На замовлення)

Energy Restoration Supplement
The active ingredient, D-fructose-1,6-diphosphate, is an intermediate product of cellular metabolism. In other words, it is a precursor to ATP. Naturally, increasing the concentration of this substance in the blood leads to accelerated recovery of energy reserves lost during training.
In the preparation of high-level athletes, especially in speed-strength sports, this supplement has proven to be highly effective and is currently one of the most advanced and widely used.
Active Ingredient:
- D-Fructose-1,6-diphosphate sodium salt in lyophilized powder 5g.
- D-Fructose-1,6-diphosphoric acid 3.75g.
Therapeutic Indications:
- Prevention of physical overstrain and improvement of adaptation to extreme physical exertion.
- Treatment of myocardial ischemic diseases - ischemia and acute myocardial infarction (as part of complex therapy) in addition to cardiokinetic therapy.
- Hypophosphatemia, objectively established in both acute situations and during transfusion therapy, surgical intervention, parenteral nutrition, as well as in chronic diseases associated with reduced phosphate levels, such as chronic alcoholism, prolonged fasting, chronic respiratory failure, malabsorption, severe burns.
- Operations using extracorporeal circulation.
- Peripheral circulatory disorders of the ischemic type.
- Acute alcohol intoxication, alcohol withdrawal syndrome, chronic alcoholism.
Contraindications:
Known hypersensitivity to the drug, hyperphosphatemia, renal failure.
Method of Administration:
Injection is administered intravenously at 10 ml per minute.
The package contains 1 vial.
The active ingredient, D-fructose-1,6-diphosphate, is an intermediate product of cellular metabolism. In other words, it is a precursor to ATP. Naturally, increasing the concentration of this substance in the blood leads to accelerated recovery of energy reserves lost during training.
In the preparation of high-level athletes, especially in speed-strength sports, this supplement has proven to be highly effective and is currently one of the most advanced and widely used.
Active Ingredient:
- D-Fructose-1,6-diphosphate sodium salt in lyophilized powder 5g.
- D-Fructose-1,6-diphosphoric acid 3.75g.
Therapeutic Indications:
- Prevention of physical overstrain and improvement of adaptation to extreme physical exertion.
- Treatment of myocardial ischemic diseases - ischemia and acute myocardial infarction (as part of complex therapy) in addition to cardiokinetic therapy.
- Hypophosphatemia, objectively established in both acute situations and during transfusion therapy, surgical intervention, parenteral nutrition, as well as in chronic diseases associated with reduced phosphate levels, such as chronic alcoholism, prolonged fasting, chronic respiratory failure, malabsorption, severe burns.
- Operations using extracorporeal circulation.
- Peripheral circulatory disorders of the ischemic type.
- Acute alcohol intoxication, alcohol withdrawal syndrome, chronic alcoholism.
Contraindications:
Known hypersensitivity to the drug, hyperphosphatemia, renal failure.
Method of Administration:
Injection is administered intravenously at 10 ml per minute.
The package contains 1 vial.